Oragenics, Inc. (0A64.L)
| Previous close | 2.7500 |
| Open | 3.0207 |
| Bid | 0.0000 x N/A |
| Ask | 0.0000 x N/A |
| Day's range | 3.0207 - 3.0207 |
| 52-week range | 3.0207 - 3.0207 |
| Volume | |
| Avg. volume | N/A |
| Market cap | N/A |
| Beta (5Y monthly) | 0.40 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.1420 |
| Earnings date | 29 Mar 2023 - 11 Apr 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Oragenics Announces Positive Results in Several Lantibiotics Compounds Against MRSA and VRE
TAMPA, Fla., March 14, 2023--Oragenics, Inc. (NYSE American: OGEN) ("Oragenics" or the "Company"), a biotechnology company dedicated to fighting infectious diseases, today reports favorable findings from third party laboratory testing of several compounds in Oragenics’ lantibiotics platform to combat multiple pathogens despite the resistance of those pathogens to standard-of-care antibiotics. Lantibiotics are a novel class of antibiotics with the potential to treat serious, life-threatening infe
- Business Wire
Oragenics Appoints Janet Huffman as Chief Financial Officer Strengthening Executive Leadership Team
TAMPA, Fla., March 08, 2023--Oragenics, Inc. (NYSE American: OGEN) ("Oragenics" or the "Company"), a biotechnology company dedicated to fighting infectious diseases including COVID-19, announces the appointment of Janet Huffman as Chief Financial Officer, effective March 7, 2023. Ms. Huffman is a seasoned financial executive with more than a dozen years of leadership experience at publicly traded and private healthcare companies.
- Business Wire
Oragenics Enters into an Exclusive Global License Agreement with Inspirevax to Develop Intranasal Covid Vaccine Candidate
TAMPA, Fla., March 01, 2023--Oragenics, Inc. (NYSE American: OGEN) ("Oragenics" or the "Company"), a biotech company dedicated to fighting infectious diseases including COVID-19, today announced that the Company has entered into an exclusive global license agreement with Inspirevax Inc. for its novel intranasal mucosal adjuvant, BDX301, for the development of NT-CoV2-1, Oragenics’ lead intranasal COVID-19 vaccine candidate.
